The MYC proto-oncogenes encode a family of transcription factors that are among the most
commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or …

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

Epigenetic dysregulation has long been recognized as a key factor contributing to
tumorigenesis and tumour maintenance that can influence all of the recognized hallmarks of …

Transcription factors are involved in a large number of human diseases such as cancers for
which they account for about 20% of all oncogenes identified so far. For long time, with the …

Dysregulated expression of the transcription factor MYCN is frequently detected in nervous
system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a …

Neuroblastoma is a neural crest derived malignancy of the peripheral nervous system and is
the most common and deadliest tumor of infancy. It is characterized by clinical heterogeneity …

MYCN amplification is tightly associated with the poor prognosis of pediatric neuroblastoma
(NB). The regulation of NB cell death by MYCN represents an important aspect, as it directly …

The pathophysiological roles and the therapeutic potentials of Myc family are reviewed in
this article. The physiological functions and molecular machineries in stem cells, including …

Transcription of the ribosomal RNA genes (rDNA) that encode the three largest ribosomal
RNAs (rRNA), is mediated by RNA Polymerase I (Pol I) and is a key regulatory step for …

Osteosarcoma (OS) is a primary malignant bone tumor that most commonly affects children,
adolescents, and young adults. Here, we comprehensively analyze genomic, epigenomic …